WebOncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO. Benzinga. Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat ... Web22 mrt. 2024 · See the latest Immuneering Corp Class A stock price (NASDAQ:IMRX), related news, valuation, dividends and more to help you make your investing decisions.
IMRX Stock Price Immuneering Corp. Stock Quote (U.S.: Nasdaq ...
Web15 feb. 2024 · Volatility Over Time: IMRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks. About the Company Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. WebBe the first to know when Wall Street analysts revise their IMRX stock forecasts and price targets. Get Free IMRX Updates. IMRX stock forecasts by analyst. All Analysts Top Analysts. ... and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.02%.Immuneering 's revenue in 2024 is $506,088. reclined figure four
Buy Immuneering Corp Stock IMRX Stock Price Today & News
Web15 mrt. 2024 · IMRX Immuneering Corp. Stock Price & News - WSJ 0.01% Immuneering Corp. IMRX (U.S.: Nasdaq) AT CLOSE 4:00 PM EDT 04/06/23 $9.78USD 1.42 16.99% … Web13 apr. 2024 · About IMRX Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product … Web12 aug. 2024 · About SEC Filings. Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia ... reclined figure four stretch